Investor Presentaiton

Targeted Protein Degradation offers the promise of novel targets and clinical differentiation for existing targets Expanded universe of targets (e.g., scaffolding proteins, transcription factors) Drugged: Target with approved drugs (3%) "Dark 659 Genome": (3%) 1,607 No known disease 6,007 (30%) association (30%) Human protein - Coding genes -20,000 Ill Bristol Myers Squibb™ Druggable: No approved drugs, but bind small molecules with high potency (8%) (8%) 12,139 (61%) Disease- relevant: No known potent binders, but implicated in disease (61%) Small molecule enzyme inhibitor Not for Product Promotional Use 29

View entire presentation